PriceTargets.com logo

Portage Biotech - PRTG Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 4,247.83%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 07/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PRTG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Portage Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTG

Analyst Price Target is $8.50
▲ +4,247.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Portage Biotech in the last 3 months. The average price target is $8.50, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 4,247.83% upside from the last price of $0.20.

This chart shows the closing price for PRTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Portage Biotech. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2024HC WainwrightDowngradeBuy ➝ NeutralLow
11/29/2023HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $6.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00Low
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00Low
8/2/2023HC WainwrightLower TargetBuy ➝ Buy$21.00 ➝ $9.00Low
8/1/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$16.00 ➝ $11.00Low
12/1/2022HC WainwrightLower TargetBuy$22.00 ➝ $21.00Low
11/30/2022Cantor FitzgeraldLower Target$26.00 ➝ $18.00Low
11/30/2022OppenheimerLower TargetOutperform$26.00 ➝ $18.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/20/2022HC WainwrightLower TargetBuy$32.00 ➝ $22.00Low
7/15/2022OppenheimerInitiated CoverageBuy$26.00Low
3/7/2022HC WainwrightInitiated CoverageBuy$32.00Medium
9/20/2021OppenheimerInitiated CoverageOutperform$30.00High
9/2/2021B. RileyInitiated CoverageBuy$40.00Low
8/19/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Low
(Data available from 7/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Portage Biotech logo
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Read More

Today's Range

Now: $0.20
Low: $0.19
High: $0.20

50 Day Range

MA: $0.23
Low: $0.15
High: $0.48

52 Week Range

Now: $0.20
Low: $0.13
High: $3.25

Volume

165,639 shs

Average Volume

463,215 shs

Market Capitalization

$3.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Portage Biotech?

The following Wall Street research analysts have issued stock ratings on Portage Biotech in the last year: Cantor Fitzgerald, and HC Wainwright.
View the latest analyst ratings for PRTG.

What is the current price target for Portage Biotech?

2 Wall Street analysts have set twelve-month price targets for Portage Biotech in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 4,247.8%. Cantor Fitzgerald has the highest price target set, predicting PRTG will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Portage Biotech in the next year.
View the latest price targets for PRTG.

What is the current consensus analyst rating for Portage Biotech?

Portage Biotech currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PRTG.

What other companies compete with Portage Biotech?

Other companies that are similar to Portage Biotech include Houston American Energy, New Concept Energy, Petróleo Brasileiro S.A. - Petrobras, Tamboran Resources and Woodside Energy Group. Learn More about companies similar to Portage Biotech.

How do I contact Portage Biotech's investor relations team?

Portage Biotech's physical mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The company's listed phone number is 416-929-1806. The official website for Portage Biotech is www.portagebiotech.com. Learn More about contacing Portage Biotech investor relations.